A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
A phase 2 trial of Cisplatin, Tislelizumab and Capecitabine in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
Overview
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] is a phase 2 interventional study registered as NCT07331155 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12-26. Interventions recorded: LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection, Tislelizumab Injection, 5-Fluorouracil injection and Capecitabine tablets.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Shares Nanjing Leads Biolabs, Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Shares Nanjing Leads Biolabs, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialClinical Studies for the Treatment of Advanced Solid Tumors
Shares Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Tislelizumab, Cisplatin and the tag pipeline.